Page 3 - தூங்கு கோளாறுகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Eisai Launches In-house Developed Anti-insomnia Drug Dayvigo (Lemborexant) In Hong Kong First Launch For Dayvigo In Asia Outside Of Japan TOKYO, July 1, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has launched the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. Eisai received approval for DAYVIGO in Hong Kong on February 28, 2021, and this launch is the first for DAYVIGO in Asia outside of Japan. DAYVIGO is a dual orexin receptor antagonist that inhibits orexin neurotransmission regulating sleep-wake rhythm by binding competitively to the two subtypes of orexin receptors (OX1R and OX2R). DAYVIGO acts on the orexin neurotransmitter system and is believed to facilitate sleep onset, sleep maintenance, and wake by regulating sleep-wake rhythm.

United statesHong kongAsia hong kongEisai hong kong co ltdEisai co ltdInstitute of medicineNational institute of public healthNational academiesInternational statistical classification of diseasesHealth problemsAmerica insomniaGeneric nameSleep wake disordersIrregular sleep wake rhythm disorderAnti insomnia drug marketClin sleep